A Phase 3 clinical trial involving desmopressin was updated on October 30, 2026. The trial, registered as NCT06020495 and titled "Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia," is currently listed as recruiting.
The study is evaluating desmopressin, also known as DDAVP, for its systematic use in managing severe hyponatremia. Specifically, the trial focuses on preventing serum sodium overcorrection during treatment of this condition. Desmopressin remains an approved compound.
According to the registry listing, the trial is in Phase 3 and is actively enrolling participants as of the update date. No results have been posted at this stage of the trial. The study status reflects ongoing recruitment rather than completed findings.
This update reflects only the trial's registration status and does not indicate any outcomes, efficacy data, or safety findings at this time. Further information about the trial's design, objectives, and eventual results will depend on future updates to the registry listing.
Readers interested in learning more about desmopressin can refer to the compound overview for additional background and context.